… underestimate of the association of BRAF V600E with PTC mortality in … thyroid cancer in
conventionally high-risk patients, 3 which, as the present study showed, is where BRAF V600E …

… BRAF(V600E) mutation is the most frequent genetic alteration in papillary thyroid carcinomas
(PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship between …

… BRAF V600E mutation is the most common genetic alteration found in papillary thyroid cancer
(… the prevalence of the BRAF V600E mutation in tumor samples and its association with …

… presenting annually (seer.cancer.gov). The most common form of thyroid cancer is papillary
thyroid cancer (PTC), comprising 65–88% of all differentiated thyroid cancers (1). Although …

… The aim of the present study was to correlate BRAF V600E retrospectively with different clinical
… Moreover, we investigated the relationship between BRAF V600E and the degree of PTC …

… aggressiveness will help establish a novel paradigm for treatment of thyroid cancers harboring
BRAF V600E . Furthermore, identifying downstream events from the BRAF V600E /ERK1/…

… BRAF with knockdown, or using a drug (PLX4720) designed to selectively deactivate BRAF
V600E in those thyroid cancer … human thyroid cancer cells harboring BRAF V600E prevents …

… Between January 2015 and July 2018, 2850 patients were diagnosed with thyroid cancer. …
with other types of thyroid carcinoma. PTC patients without BRAF V600E status or lost to follow…

… the impact of BRAF V600E in a large consecutive cohort of patients treated for thyroid cancer
at a single-tertiary Australian institution. The proportion of BRAF V600E -positive PTCs in …

… of BRAF V600E in thyroid carcinoma specimens and cell lines, we hypothesized that B-Raf
expression would be crucial in at least a subset of thyroid carcinomas. To deplete cells of …